Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist

European Journal of Pharmacology

Volumn 552, Issue 1-3, 2006, Pages 36-45

  Heinrich, Julia N ^a   Brennan, Julie ^a   Lai, Margaret H ^a   Sullivan, Kelly ^a   Hornby, Geoff ^a   Popiolek, Mike ^a   Jiang, Li Xin ^a   Pausch, Mark H ^a   Stack, Gary ^a   Marquis, Karen L ^a   Andree, Terrance H ^a  

^a PFIZER INC   (United States)

Author keywords

35S GTP S; Aplindore; Chimeric G q o protein; Dopamine D2 receptor; ERK phosphorylation; Intracellular calcium flux; Unilaterally 6 hydroxydopamine lesioned rat

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; APLINDORE; APOMORPHINE; ARIPIPRAZOLE; CALCIUM ION; DAB 452; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CHLORO 6 METHYLERGOLIN 8ALPHA YL)PIVALAMIDE; OXIDOPAMINE; PRAMIPEXOLE; PRECLAMOL; QUINPIROLE; RACLOPRIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN DAMAGE; CALCIUM TRANSPORT; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; FEMALE; FLUOROMETRY; GENETIC TRANSFECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BINDING, COMPETITIVE; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GTP-BINDING PROTEIN ALPHA SUBUNITS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INDOLES; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PHOSPHORYLATION; QUINPIROLE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECEPTORS, SEROTONIN, 5-HT2; SUBSTANTIA NIGRA;

EID: 33750473056     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.063     Document Type: Article

References (42)

1. 3 partial agonist for the treatment of schizophrenia. 38th Annual Meeting of the American College of Neuropsychopharmacology (Acapulco, Mexico) (1999)
2. Araki T., Tanji H., Fujihara K., Kato H., Imai Y., Mizugaki M., and Itoyama Y. Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats. J. Neural Transm. 107 (2000) 873-884
3. Benkert O., Muller-Siecheneder F., and Wetzel H. Dopamine agonists in schizophrenia: a review. Eur. Neuropsychopharmacol. 5 (1995) 43-53
4. 2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
5. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2002) 323-374
6. Clarke P.B., Jakubovic A., and Fibiger H.C. Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions of d-amphetamine and apomorphine. Psychopharmacology (Berl) 96 (1988) 511-520
7. 2 dopamine receptor/G protein interaction: evidence for agonist selection of G-protein subtype. J. Biol. Chem. 276 (2001) 28667-28675
8. Coward D.M., Dixon A.K., Urwyler S., White T.G., Enz A., Karobath M., and Shearman G. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J. Pharmacol. Exp. Ther. 252 (1990) 279-285
9. Dean B., and Scarr E. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 217-225
10. 2 short dopamine receptors determined in ligand binding and functional assays. J. Neurochem. 69 (1997) 2589-2598
11. 2L cell line: evidence for induction of ligand-specific receptor states. Mol. Pharmacol. 66 (2004) 97-105
12. 2 dopamine receptors expressed in Spodoptera frugiperda 9 (Sf9) and in HEK293 cells: analysis using co-immunoprecipitation and time-resolved fluorescence resonance energy transfer. Eur. J. Biochem. 270 (2003) 3928-3938
13. αo fusion protein expressed in Sf9 cells. FEBS Lett. 545 (2003) 155-160
14. 2L dopamine receptor expressed in a cAMP-responsive luciferase reporter cell line. Biochem. Pharmacol. 56 (1998) 25-30
15. 2 receptor directs specificity of coupling to G-proteins. J. Biol. Chem. 270 (1995) 7354-7358
16. Inoue A., and Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn. J. Pharmacol. 86 (2001) 376-380
17. 2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol. 321 (1997) 105-111
18. Kostenis E., Waelbroeck M., and Milligan G. Techniques: promiscuous Gα proteins in basic research and drug discovery. Trends Pharmacol. Sci. 26 (2005) 595-602
19. 1A receptor coupling. Biochem. Biophys. Res. Commun. 294 (2002) 655-659
20. Kulisevsky J., and Pagonabarraga J. New treatments in movement disorders. Neurologia 19 Suppl 2 (2004) 40-63
21. 2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol. Pharmacol. 42 (1992) 432-438
22. Lauterbach E.C. The neuropsychiatry of Parkinson's disease. Minerva Med. 96 (2005) 155-173
23. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., and Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
24. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18 (2004) 251-267
25. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
26. Meller E., Helmer-Matyjek E., Bohmaker K., Adler C.H., Friedhoff A.J., and Goldstein M. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur. J. Pharmacol. 123 (1986) 311-314
27. 2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. J. Med. Chem. 40 (1997) 4235-4256
28. 2 receptors: II. actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J. Pharmacol. Exp. Ther. 309 (2004) 921-935
29. 2 receptors and G-proteins. Mol. Endocrinol. 7 (1993) 161-170
30. Nirenberg M.J., and Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov. Disord. 4 (2006) 524-529
31. Reynolds G.P. Receptor mechanisms in the treatment of schizophrenia. J. Psychopharmacol. 18 (2004) 340-345
32. 2 dopamine receptors. Biochem. Pharmacol. 67 (2004) 1657-1665
33. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
34. Silverman P.B., and Ho B.T. Persistent behavioural effect in apomorphine in 6-hydroxydopamine-lesioned rats. Nature 294 (1981) 475-477
35. 2S receptors coupled to extracellular signal-regulated kinase. Eur. J. Pharmacol. 534 (2006) 63-70
36. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J. Clin. Psychiatry 62 (2001) 923-924
37. Stoessl A.J., Dourish C.T., and Iversen S.D. Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. Psychopharmacology (Berl) 93 (1987) 336-342
38. 2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 515 (2005) 10-19
39. Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J. Neural Transm. 109 (2002) 411-420
40. Tamminga C.A., and Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 141-147
41. 2(short) dopamine receptors. Neurosci. Lett. 280 (2000) 135-138
42. 3 receptors in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 290 (1999) 908-916